Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1998-06-18
1999-05-04
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 3144
Patent
active
059004207
ABSTRACT:
The present invention encompasses methods for treating chronic fatigue syndrome and fibromyalgia by administering buprenorphine or a salt thereof. The compound may optionally be administered in a pharmaceutical composition. Preferred compositions for delivery of the buprenoiphine are sublingual lozenges and transdermal gel.
REFERENCES:
patent: 5013739 (1991-05-01), Bihari et al.
patent: 5545670 (1996-08-01), Bissbort et al.
Borenstein, D., Prevalence and Treatment Outcome of Primary and Secondary Fibromyalgia In Patients With Spinal Pain, Spine, vol. 2, No. 7, pp. 796-800, Apr. 1, 1995 (Abstract Only).
Budavari, S. et al., The Merck Index--An Encyclopedia of Chemicals, Drugs and Biologicals--1487--Eleventh Edition, 1989 p. 228.
Fukada, et al. The Chronic Fatigue Syndrome: A Comprehensive Approach to Its Definition and Study. Annals of Internal Medicine. vol. 121(12), Dec. 15, 1994. pp. 953-959.
Goodman & Gilman's The Pharmacological Basis of Therapeutics. 1996, pp. 618-622.
Gylys. Pharmacology. The Journal of Cardiovascular Nursing. vol. 12(3), Apr. 1998. pp. 52-56.
Holmes, et al. Chronic Fatigue Syndrome: A Working Case Definition. Annals of Internal Medicine. vol. 108. 1988, pp. 387-389.
Calabrese, et al. "Chronic Fatigue Syndrome", American Family Physician, vol. 45, No. 3, pp. 1205-1213 (1992).
Oliveto, et al. "Buprenorphine", The new pharmacotherapies, pp. 255-265 (1992).
Cox, et al. "Red blood cell magnesium and chronic fatigue syndrome" The Lancet, vol. 337, pp. 757-760 (1991).
CDC CFS Research Group, Center Disease Control, Atlanta, GA, "Chronic Fatigue Syndrome Research at the CDC", the CFIDS Chronicle Physician's Forum, pp. 50-77 (1992).
Collinge, William "Recovering from Chronic Fatigue Syndrome: A guide to self-empowerment" pp. 40-41 (1993).
Cheney, et al., "The diagnosis of chronic fatigue syndrome: an assertive approach", the CFIDS Chronicle Physician's Forum, pp. 13-19 (1992).
Vanderzalm, Lynn, "Riding the emotional roller-coaster of CFIDS", The CFIDS Chronicle, pp. 19-21 (1997).
Peterson et al., "Effects of mild exercise on cytokines and cerebral blood flow in chronic fatigue syndrome patients" Clin. Diagn. Lab. Immunol. vol. 1, No. 2 pp. 222-226 (1994).
Mawle, A.C., "Chronic fatigue syndrome", Immunological investigations, 26(1 and 2) pp. 269-273 (1997).
DiPino, et al., "Neurocognitive functioning in chronic fatigue syndrome", neuropsychology review, vol. 6, No. 1, pp. 47-60 (1996).
Cleare, et al. "Contrasting neuroendocrine responses in depression and chronic fatigue syndrome", Jour. Affective Disorders 35, pp. 283-289 (1995).
"Chronic Fatigue Syndrome", National Institute of Allergy and Infectious Diseases, Spring 1994.
Kantrowitz, et al. "Chronic fatigue syndrome 2: treatment and future research", Behav. Med., vol. 21, pp. 17-23 (1995).
Suhadolnik, et al. "Biochemical evidence for a novel low molecular weight 2-5A-Dependent RNase L in Chronic Fatigue Syndrome", Jour. of Interferon and Cytkine Research vol. 17, pp. 377-385 (1997).
Bearn, et al. "Neurobiological aspects of the chronic fatigue syndrome", Eur. Jour. of Clin. Investigation, vol. 24, pp. 79-90 (1994).
Dinan, et al. "Blunted serotonin-mediated activation of the hypothalmic-pituitary-adrenal axis in chronic fatigue syndrome", Psychoneuroendocrinology, vol. 22, No. 4, pp. 261-267 (1997).
McBride, et al., "Treatment of chronic fatigue syndrome", Brit. Med. Bulletin, vol. 47, No. 4, pp. 895-907 (1991).
Koopman, "Cytokines and their receptors in arthritis and allied conditions" (1997).
Goldstein, Jay A., "The diagnosis of chronic fatigue syndrome as a limbic encephalopathy", The CFIDS Chronicle Physicians Forum, pp. 20-31 (1992).
Hendrick, Bill, "The enemy within", The Atlanta Jour. and Constitution, Section E, Jun. 17, 1995.
Cleare, Anthony J., "Letters to the Editor", Can. Jour. of Psychiatry, vol. 41, No. 2 (1996).
Mello, Nancy K. "Comparison of Buprenorphine and Methadone Effects on Opiate Self-Administration in Primates", Jour. of Pharmacology and Experimental Therapeutics, vol. 225, No. 2 (1983).
English, Thomas L. "Skeptical of Skeptics", J.A.M.A. ed. 27, vol. 265, No. 8, p. 964 (1991).
Komaroff, et al. "An Examination of the Working Case Definition of Chronic Fatigue Syndrome", Am J. Med., vol. 100, pp. 56-64 (1996) (Abstract only).
Farmer, et al. "Screening for Psychiatric Morbidity in Subjects Presenting with Chronic Fatigue Syndrome", Br. J. Psychiatry, vol. 168, pp. 354-358 (1996) (Abstract only).
Cannon, et al. "Interleukin-1 beta, interleukin-1 receptor antagonist, and soluble interleukin-1 receptor type secretion in chronic fatigue syndrome", J. Clin. Immunol., vol. 17, pp. 253-261 (1997) (Abstract only).
Bodkin, et al. "Buprenorphine Treatment of Refractory Depression", J. Clin. Psychopharmacol., vol. 15/No. 1, pp. 49-57 (1995).
Mawle et al. "Immune Reponses Associated with Chronic Fatigue Syndrome: A case-control study" J. Infect. Dis., vol. 175, pp/ 136-141 (1997) (Abstract only).
Marcel, et al. "Cognitive Deficits in Patients with Chronic Fatigue Syndrome" Bio. Psychiatry, vol. 40, pp. 535-541 (1996) (Abstract only).
Cheng, et al. "N-cubylmethyl Substituted Morphinoids as Novel Narcotic Antagonists" Bioorg. Med. Chem., vol. 4, pp. 73-80 (1996) (Abstract only).
"Chronic Fatigue Syndrome Information for Physicians", NIH Publication No. 96-484, Sep. 1996.
Lewis, et al., "Buprenorphine: Background to its development as a treatment for opiate dependence", J.D. Blaine, Ed., Buprenorphine: Alternative treatment for opioid dependence. NIDA Monograph No. 121, pp. 5-11 (1992) (Abstract only).
Banys, et al., "An open trial of low dose buprenorphine in treating methadone withdrawl", Journal of Substance abuse Treatment pp. 9-15 (1994) (Abstract only).
Bevan, et al. "Sublingual bioavailability of buprenorphine at analgesic doses", L.S. Harris, ed., Problems of drug dependence, 1995: Proceedings of the 57th annual scientific meeting, college on problems of drug dependence. NIDA research monograph 162 (1995) (Abstract only).
Wallenstein, et al. "Clinical analgesic assay of sublingual buprenorphine and intramuscular morphine", Problems of drug dependence, 1981: Proceedings of the 43rd annual scientific meeting, committee on problems of drug dependence. NIDA research monograph 41 (1981) (Abstract only).
Jeffcoat, et al. "Human disposition of intravenous, oral and sublingual Proceedings of the 54th annual scientific meeting, college on problems of the drug dependence. NIDA research monograph 132 (1993) (Abstract only).
Banys, et al. "Pilot study with low-dose buprenorphine", L. Harris, ed. Problems of drug dependence, 1991: Proceedings of the 53rd annual scientific meeting, committee on problems of drug dependence. NIDA research monograph 119, p. 360 (1995) (Abstract only).
Mendelson, et al. "Buprenorphine pharmacokinetics: Bioavailability of an 8mg sublingual tablet formulation", L.S. Harris, ed. Problems of drug dependence, 1995: Proceedings of the 57th annual scientific meeting, college on problems of drug dependence. NIDA research monograph 162, p. 112 (1995) (Abstract only).
Cone, et al. "Elevated drug saliva levels suggest a `sepot-like` effect in subjects treated with sublingual buprenorphine", L. Harris, ed. Problems of drug dependence, 1990: Proceedings of the 52nd annual scientific meeting, college on problems of drug dependence. NIDA research monograph 105, p. 569 (1995) (Abstract only).
"Prefin* brand of Buprenorphine Hydrochloride", RxMed, pp. 1-6, Website: http://www.rxmed.com/monographs2/preferin.html (1997).
"What Is CFIDS.M.E.?", WECAN, Inc., pp. 1-3 (1997) Website: http://www.community-care.org.UK/wecan/handout.html.
"The Facts About Chronic Fatigue Syndrome", Centers for Disease Control and Prevention--National Center For Infectious Diseases--Atlanta, Georgia (Mar. 1995) pp. 1-13 Website:http://www.dds.nl/.about.me-net/meweb/cdcfacts.txt.
"The Quality Of Mercy", U.S. News On Line, pp. 1-8 (1997) Website:http://www.usnews.com/usnews/issue/970317/17pain.htm.
"Table 5. Dosing for Opioid Analgesics", pp. 1-3 (1997) Website: http://www.roxane.com/Roxane/RPI/HealthcareProfessionalLibrary
LandOfFree
Method for treating chronic fatigue syndrome and fibromyalgia wi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating chronic fatigue syndrome and fibromyalgia wi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating chronic fatigue syndrome and fibromyalgia wi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1869667